MedTrace Logo

CARv3-TEAM-E T Cells in Glioblastoma

NCT05660369 · Status: RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 21

Last updated 2026-02-04

No results posted yet for this study

Summary

The goal of this research study is to determine the best dose of CARv3-TEAM-E T Cells for treating participants with glioblastoma.

The name of the treatment intervention used in this research study is:

-CARv3-TEAM-E T Cells (or Autologous T lymphocytes).

Conditions

Interventions

DRUG

CARv3-TEAM-E T cells

Autologous T lymphocyte population that contains cells transduced ex-vivo with a CARv3-TEAM-E lentiviral vector encoding a chimeric antigen receptor (CAR). Administered via Ommaya reservoir.

Sponsors & Collaborators

  • Marcela V. Maus, M.D.,Ph.D.

    lead OTHER

Principal Investigators

  • William Curry, MD · Massachusetts General Hospital

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-03-22
Primary Completion
2026-09-01
Completion
2027-09-01
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05660369 on ClinicalTrials.gov